EMA chooses first two drugs for adaptive licensing scheme
This article was originally published in SRA
Executive Summary
The European Medicines Agency has selected the first two medicines to enter its pilot adaptive licensing project, out of a total of 20 applications received from companies so far. It is considering four more as potential candidates to be included at a later stage, has rejected three as being unsuitable, and is still evaluating the remaining 11.